The Watchman Device: An Alternative Treatment in Atrial Fibrillation
Anastasia Palmer, Ahmned Mohamed, & Shiader Thao
Abstract
Stroke prevention is an important aspect in the management of Atrial Fibrillation (AFib). The 2019 Guideline for Management of Patients with Atrial Fibrillation recommends DOACs as first line, but warfarin is also still widely used. These medications are effective but their systemic effect on the body require careful monitoring to avoid serious adverse events, contraindications, and other drug-drug interactions. As a result, many patients do not adhere or cannot tolerate the medications, therefore physicians continue to search for alternatives. The latest focus has been on the Watchman Device, a device that essentially seals off the left atrial appendage closure (LAAC). The LAAC is an area in the heart where blood clots often form in patients with AFib. The Watchman device prevents the clots in this area from escaping, lowering the risk of stroke. Though the Watchman device has been shown to be an effective non-pharmacological substitute, careful patient consideration remains an emphasis when choosing treatment. Staying informed and knowing what treatment options are available, along with understanding the patient and his/her preferences, can aid in deciding on the most effective option to prevent stroke.
Full Text
Vol3Article4.pdf
File Size: 258 kb
File Type: pdf
Download File

Notice and Disclaimer

Medicine is an ever-changing science.  As new research and clinical experience broaden our knowledge, changes in treatment and drug therapy are required.  The authors and the publisher of this work have checked with sources believed to be reliable in their efforts to provide information that is complete and generally in accord with the standards accepted at the time of publication.  However, in view of the possibility of human error or changes in medical sciences, neither the authors nor the publisher nor any other party who has been involved in the preparation or publication of this work warrants that the information contained herein is accurate or complete, and they disclaim all responsibility for any errors or omissions or for the results obtained from use of the information contained in this work.    Readers are encouraged to confirm the information contained herein with other sources.   For example and in particular, readers are advised to check the product information sheet included in the package of each drug they plan to administer to be certain that the information contained in this work is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.

Subscribe to ARxCH